{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:05:00Z","timestamp":1762459500514,"version":"3.37.3"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"suppl_9","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI068581"],"award-info":[{"award-number":["AI068581"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"DOI":"10.1093\/infdis\/jix398","type":"journal-article","created":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T19:10:25Z","timestamp":1502305825000},"page":"S843-S846","source":"Crossref","is-referenced-by-count":14,"title":["Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update"],"prefix":"10.1093","volume":"216","author":[{"given":"Robert W","family":"Shafer","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Stanford University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,9,15]]},"reference":[{"key":"key\n\t\t\t\t20180306121503_CIT0001","first-page":"132","article-title":"2017 update of the drug resistance mutations in HIV-1","volume":"24","author":"Wensing","year":"2017","journal-title":"Top Antivir Med"},{"key":"key\n\t\t\t\t20180306121503_CIT0002","doi-asserted-by":"crossref","first-page":"e0181357","DOI":"10.1371\/journal.pone.0181357","article-title":"Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation","volume":"12","author":"Paredes","year":"2017","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180306121503_CIT0003","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","article-title":"Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments","volume":"98","author":"Men\u00e9ndez-Arias","year":"2013","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20180306121503_CIT0004","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","article-title":"HIV-1 drug resistance and resistance testing","volume":"46","author":"Clutter","year":"2016","journal-title":"Infect Genet Evol"},{"key":"key\n\t\t\t\t20180306121503_CIT0005","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ebiom.2017.03.024","article-title":"Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an international collaboration","volume":"18","author":"Rhee","year":"2017","journal-title":"EBioMedicine"},{"key":"key\n\t\t\t\t20180306121503_CIT0006","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","author":"TenoRes Study Group","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180306121503_CIT0007","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.antiviral.2007.03.006","article-title":"Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase","volume":"75","author":"Kagan","year":"2007","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20180306121503_CIT0008","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1128\/AAC.00683-06","article-title":"Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors","volume":"51","author":"Sluis-Cremer","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306121503_CIT0009","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/AAC.05487-11","article-title":"Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility","volume":"56","author":"Melikian","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306121503_CIT0010","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/QAI.0b013e31817bbe93","article-title":"The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation","volume":"48","author":"Svarovskaia","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180306121503_CIT0011","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1128\/AAC.00816-06","article-title":"In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine","volume":"50","author":"Margot","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306121503_CIT0012","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/378281","article-title":"Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates","volume":"188","author":"Whitcomb","year":"2003","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306121503_CIT0013","doi-asserted-by":"crossref","first-page":"e16242","DOI":"10.1371\/journal.pone.0016242","article-title":"K70Q adds high-level tenofovir resistance to \u201cQ151M complex\u201d HIV reverse transcriptase through the enhanced discrimination mechanism","volume":"6","author":"Hachiya","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180306121503_CIT0014","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2016.05.012","article-title":"High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate","volume":"132","author":"Margot","year":"2016","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20180306121503_CIT0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.antiviral.2017.03.021","article-title":"Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation","volume":"143","author":"Cox","year":"2017","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20180306121503_CIT0016","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3125","article-title":"Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide or elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate","author":"Margot","year":"2017","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180306121503_CIT0017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jac\/dkt316","article-title":"Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing","volume":"69","author":"Melikian","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180306121503_CIT0018","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3851\/IMP2771","article-title":"Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine","volume":"19","author":"Picchio","year":"2014","journal-title":"Antivir Ther"},{"volume-title":"Combinations of HIV-1 reverse transcriptase mutations L100I + K103N\/S and L100I + K103R + V179D reduce susceptibility to rilpivirine","author":"Haddad","key":"key\n\t\t\t\t20180306121503_CIT0019"},{"volume-title":"Mutation Y188L of HIV-1 reverse transciptase is strongly associated with reduced susceptibility to rilpivirine","year":"2012","author":"Haddad","key":"key\n\t\t\t\t20180306121503_CIT0020"},{"key":"key\n\t\t\t\t20180306121503_CIT0021","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3851\/IMP2636","article-title":"96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE phase III trials","volume":"18","author":"Rimsky","year":"2013","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180306121503_CIT0022","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/QAI.0b013e3182237f74","article-title":"Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine","volume":"58","author":"Tambuyzer","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180306121503_CIT0023","article-title":"Comparison of the Antivirogram and PhenoSense assays to determine phenotypic susceptibility to rilpivirine in patient samples from the Phase III ECHO and THRIVE trials","volume-title":"International Workship on HIV and Hepatitis Drug Resistance and Curative Strategies","author":"Van Eygen","year":"2012"},{"key":"key\n\t\t\t\t20180306121503_CIT0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.antiviral.2014.04.001","article-title":"E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings","volume":"107","author":"Sluis-Cremer","year":"2014","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t20180306121503_CIT0025","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.04215-14","article-title":"Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors","volume":"59","author":"Basson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306121503_CIT0026","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/aid.2015.0095","article-title":"Sub-epidemics explain localized high prevalence of reduced susceptibility to rilpivirine in treatment-naive HIV-1-infected patients: subtype and geographic compartmentalization of baseline resistance mutations","volume":"32","author":"Theys","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180306121503_CIT0027","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/QAD.0000000000000140","article-title":"Occurrence of etravirine\/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy","volume":"28","author":"Crawford","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180306121503_CIT0028","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/QAI.0000000000001285","article-title":"HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in Sub-Saharan Africa","volume":"75","author":"Kityo","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180306121503_CIT0029","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1089\/aid.2015.0331","article-title":"Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE Study","volume":"32","author":"Lam","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180306121503_CIT0030","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0000000000000485","article-title":"A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses","volume":"28","author":"Kolomeets","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180306121503_CIT0031","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/infdis\/jiw219","article-title":"Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in sub-Saharan Africa","volume":"214","author":"Boender","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306121503_CIT0032","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/QAD.0000000000001500","article-title":"Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya","volume":"31","author":"Inzaule","year":"2017","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180306121503_CIT0033","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkr569","article-title":"Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir\/ritonavir as their first protease inhibitor","volume":"67","author":"Barber","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180306121503_CIT0034","first-page":"2339","article-title":"Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study","volume":"68","author":"Dolling","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180306121503_CIT0035","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/infdis\/jis613","article-title":"HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status","volume":"206","author":"Mollan","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306121503_CIT0036","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1093\/jac\/dkw343","article-title":"HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK","volume":"71","author":"El Bouzidi","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180306121503_CIT0037","doi-asserted-by":"crossref","first-page":"e86239","DOI":"10.1371\/journal.pone.0086239","article-title":"Comparable long-term efficacy of lopinavir\/ritonavir and similar drug-resistance profiles in different HIV-1 subtypes","volume":"9","author":"Grossman","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180306121503_CIT0038","article-title":"HIV-1 protease inhibitors resistance profiles in patients with virological failure on LPV\/r based 2nd line regimen in Cambodia","volume":"S5","author":"Nerrienet","year":"2012","journal-title":"J AIDS Clin Res"},{"key":"key\n\t\t\t\t20180306121503_CIT0039","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3851\/IMP3005","article-title":"HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda","volume":"21","author":"Ndahimana","year":"2016","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180306121503_CIT0040","doi-asserted-by":"crossref","first-page":"e67188","DOI":"10.1371\/journal.pone.0067188","article-title":"Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens","volume":"8","author":"Van Zyl","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180306121503_CIT0041","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/nm.2892","article-title":"Antiretroviral dynamics determines HIV evolution and predicts therapy outcome","volume":"18","author":"Rosenbloom","year":"2012","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20180306121503_CIT0042","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1086\/380509","article-title":"Incidence of resistance in a double-blind study comparing lopinavir\/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine","volume":"189","author":"Kempf","year":"2004","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306121503_CIT0043","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/cid\/ciu367","article-title":"Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens","volume":"59","author":"Zheng","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306121503_CIT0044","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/cid\/cix015","article-title":"Virological outcomes of second-line protease inhibitor-based treatment for human immunodeficiency virus type 1 in a high-prevalence rural South African setting: a competing-risks prospective cohort analysis","volume":"64","author":"Collier","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306121503_CIT0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1742-4690-9-63","article-title":"Human immunodeficiency virus Gag and protease: partners in resistance","volume":"9","author":"Fun","year":"2012","journal-title":"Retrovirology"},{"key":"key\n\t\t\t\t20180306121503_CIT0046","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1089\/aid.2015.0138","article-title":"Gag-protease sequence evolution following protease inhibitor monotherapy treatment failure in HIV-1 viruses circulating in East Africa","volume":"31","author":"Sutherland","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180306121503_CIT0047","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1172\/JCI67399","article-title":"Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance","volume":"123","author":"Rabi","year":"2013","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20180306121503_CIT0048","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"key\n\t\t\t\t20180306121503_CIT0049","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/AAC.00204-13","article-title":"Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir","volume":"57","author":"Huang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306121503_CIT0050","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","volume":"31","author":"Lepik","year":"2017","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180306121503_CIT0051","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306121503_CIT0052","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3851\/IMP3033","article-title":"Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients","volume":"21","author":"Naeger","year":"2016","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180306121503_CIT0053","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"volume-title":"Pathways of resistance in subjects failing dolutegravir monotherapy [abstract 42]","author":"Blanco","key":"key\n\t\t\t\t20180306121503_CIT0054"},{"key":"key\n\t\t\t\t20180306121503_CIT0055","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/jac\/dkw071","article-title":"Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors","volume":"71","author":"Brenner","year":"2016","journal-title":"J Antimicrob Chemother"},{"volume-title":"Dolutegravir as maintenance monotherapy for HIV-1: a randomized clinical trial (451LB)","author":"Wijting","key":"key\n\t\t\t\t20180306121503_CIT0056"},{"key":"key\n\t\t\t\t20180306121503_CIT0057","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/JVI.06591-11","article-title":"Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir","volume":"86","author":"Quashie","year":"2012","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180306121503_CIT0058","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1128\/JVI.03485-14","article-title":"Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions","volume":"89","author":"Anstett","year":"2015","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180306121503_CIT0059","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1128\/AAC.01835-13","article-title":"Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase","volume":"57","author":"Quashie","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306121503_CIT0060","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/JVI.03353-14","article-title":"Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase","volume":"89","author":"Quashie","year":"2015","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180306121503_CIT0061","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306121503_CIT0062","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1128\/AAC.03909-14","article-title":"Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection","volume":"59","author":"Yoshinaga","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/216\/suppl_9\/S843\/24264688\/jix398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T23:02:11Z","timestamp":1659308531000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/216\/suppl_9\/S843\/4159365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,15]]},"references-count":62,"journal-issue":{"issue":"suppl_9","published-online":{"date-parts":[[2017,9,15]]},"published-print":{"date-parts":[[2017,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jix398","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2017,11,15]]},"published":{"date-parts":[[2017,9,15]]}}}